Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Proleukin Revenue (Q3 2024): $16.5 million. Year-to-Date Total Product Revenue (2024): $90.4 million. Amtagvi Revenue Year-to-Date (2024): $54.9 million. Proleukin Revenue Year-to-Date (2024): $35.5 million. Net Loss (Q3 2024): $83.5 million or $0.28 per share. Net Loss (First Nine Months 2024): $293.6 million or $1.03 per share. Gross Margin (Q3 2024): $25.6 million against revenue of $58.6 million. Cash Position (as of September 30, 2024): Approximately $403.8 million. Research and Development Expenses (Q3 2024): $68.2 million. Selling, General and Administrative Expenses (Q3 2024): $39.6 million. Full Year 2024 Revenue Guidance: $160 million to $165 million. Full Year 2025 Revenue Guidance: $450 million to $475 million. Cash Burn Guidance (Full Year 2024): $320 million to $340 million, excluding one-time expenses. Warning! GuruFocus has detected 2 Warning Signs with IOVA. Release Date: November 07, 2024 For the complete transcript of the earnings call
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics GAAP EPS of -$0.28 beats by $0.02, revenue of $58.6M beats by $4.78M [Seeking Alpha]Seeking Alpha
IOVA
Earnings
- 11/7/24 - Beat
IOVA
Sec Filings
- 11/21/24 - Form 8-K
- 11/14/24 - Form 4
- 11/14/24 - Form SC
- IOVA's page on the SEC website